Skip to content

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care

We Craft Care


Untitled design 2024 01 15T161519.902

compassionate care scientifically crafted

At SOMAÍ, we are on a journey to build a leading global brand with the most robust portfolio of innovative cannabis-based therapeutics. We envision a world where people live healthy lifestyles empowered by natural cannabis medicine.

Our company is dedicated to formulating innovative cannabis-based products to ensure a healthy and comfortable life. For that, we create a wide variety of medications for chronic patients and different conditions. We aim to design calm and satisfactory experience of administering, prescribing and purchasing cannabis-based medicine.

SOMAÍ Pharmaceuticals is an EU-GMP European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal, and distributing EU GMP-certified cannabinoid-containing pharmaceuticals globally. SOMAÍ emphasizes scientific pharmacology applications with EU-GMP standards to effectively and consistently deliver treatments to the endocannabinoid system across all markets.

Company News

Newsletter   2024 05 27T164049.385

Leading Canadian Cannabis Brand Ghost Drops Enters into an Agreement with SOMAÍ Group for Global Distribution

May 28, 2024

The partnership opportunely positions Ghost Drops and SOMAÍ Group to succeed in the EU, UK, and Australian Cannabis…

Read more
Newsletter   2024 05 15T211539.791

SOMAÍ Group, and its subsidiary, RPK Biopharma expand Cookies partnership to include Europe and the UK

May 16, 2024

SOMAÍ Group and its subsidiary, RPK Biopharma expanded their existing partnership with Cookies to include additional territories for…

Read more
Newsletter (2)

SOMAÍ Pharmaceuticals Introduces UK to The Most Complete Cannabis-Based Product Portfolio Following a Distribution Deal

March 12, 2024

SOMAÍ Pharmaceuticals signs distribution deal with Grow Pharma for UK’s most comprehensive range of cannabis-based medicines. This collaboration…

Read more
Newsletter 2024 02 29T155639.107

SOMAÍ Pharmaceuticals Acquires RPK Biopharma (Holigen), Reinforcing Global Leading Position in Medicinal Cannabis Sector

February 29, 2024

SOMAÍ Pharmaceuticals today announced it has entered into a definitive agreement with AKANDA Corp., an international medical cannabis…

Read more
Newsletter 92

SOMAÍ Pharmaceuticals Introducing the U.S. Award-Winning Airo Brand to European and Australian Markets

February 6, 2024

SOMAÍ Pharmaceuticals announces its partnership with AIRO BRANDS, a U.S. multi-state CPG company focused on proprietary cannabis products….

Read more
Newsletter 1920 x 950 px 4

SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany

December 21, 2023

SOMAÍ Pharmaceuticals announces a landmark three-year marketing & distribution agreement with Canify AG. This partnership signifies SOMAÍ Pharmaceuticals’…

Read more
Newsletter 84

SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal

December 14, 2023

SOMAÍ Pharmaceuticals announces its entry into the German market through partnerships with Canymed GmbH and Grünhorn, securing a…

Read More
Newsletter 1200 x 628 px 1200 x 628 px 1920 x 950 px 1

SOMAÍ Pharmaceuticals Partners with UK’s largest medical cannabis study T21 by Drug Science

December 12, 2023

SOMAÍ Pharmaceuticals is thrilled to announce partnering with the groundbreaking medical cannabis study, T21 (formerly Project TWENTY21). As…

read more
Newsletter 82

SOMAÍ Pharmaceuticals Signs Manufacturing Contract with Canna Forest

November 28, 2023

SOMAÍ Pharmaceuticals has signed a manufacturing agreement with Canna Forest to produce EU-GMP-certified extracted cannabis APIs and products…

read more
Newsletter 48

SOMAÍ Pharmaceuticals Receives EU-GMP Certification and Raises €5 million

September 1, 2023

SOMAÍ Pharmaceuticals Unipessoal LDA, the largest European pharmaceutical cannabis product manufacturer, is pleased to announce that it has…

Read more

SOMAÍ Pharmaceuticals has renewed the partnership with Lusófona University/CBIOS for formulation development

July 26, 2023

According to this partnership, Lusófona will develop lab-scale formulations and perform corresponding stability testing. The collaboration will also…

Read more
SOMAI IG Size 1920 x 950 px 5

SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Cannabis

June 12, 2023

SOMAÍ Pharmaceuticals has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis. Cosma produces…

Read more
Untitled design 38

Clever Leaves Partners with SOMAÍ Pharmaceuticals and Sends First Commercial Shipments to Portugal

May 31, 2023

SOMAÍ Pharmaceuticals Unipessoal LDA has entered into a five-year agreement with Clever Leaves Holdings Inc., a global medicinal…

Read more